Brain Screenings Offered to Breast Cancer Patients During Breast Cancer Awareness Month
Posted on: Friday, 19 October 2007, 09:00 CDT
CHICAGO, Oct. 19 /PRNewswire/ --
What: Women diagnosed with HER-2 positive Stage III or Stage IV breast cancer are eligible to receive an MRI of the brain at no charge as part of a clinical trial. HER2 is a breast cancer that tests positive for a protein called human epidermal growth factor receptor-2 (HER2), which promotes the growth of cancer cells. Studies have shown that in as many as 30 percent of breast cancer patients have a metastasis in the brain. As part of the screening protocol, participants will undergo a MRI of the brain. The cost of the MRI is covered by the clinical trial. Who: Patients who qualify must have an initial primary diagnosis of high risk and/or HER-2 positive breast cancer. They must be at least 18 years and should not participate if they are pregnant. When: Friday, October 26th, 1 p.m. to 9 p.m. Saturday, October 27th, 8 a.m. to 5 p.m. Where: Neurologic and Orthopedic Institute of Chicago 4501 N. Winchester, Chicago Cost: The brain MRI is free of charge to the patient. Background: The Chicago Institute of Neurosurgery and Neuroresearch (CINN) Medical Group will use information from the screening to determine the potentialbenefit(s) of screening for brain metastases in patients with advanced breast cancer. Study Selection & Enrollment Criteria Women must be within three to twenty-four months of first metastases of Stage IV diagnosis or within 12 to 24 months of initial diagnosis of HER-2 positive Stage III disease. They must sign a written consent form approved by the CINN Institutional Review Board (IRB). Exclusion criteria Patients with a prior diagnosis of brain metastases or who are unable to be safely exposed to MRIs. Most common exclusions include, but are not limited to, pacemakers, implanted defibrillators, neurostimulators, aneurysm clips, cochlear devices, or any other institution contraindications. Women who are pregnant.
CONTACT: Sandi Davis of Chicago Institute of Neurosurgery and Neuroresearch, 773-250-0425, http://www.cinn.org/
Media Contact: Lisa Stafford, P.S. Communications, 630-986-8749, Cell: 630-212-1226, Email: lisa@pscommunicationsinc.com
Chicago Institute of Neurosurgery and Neuroresearch
CONTACT: Sandi Davis of Chicago Institute of Neurosurgery andNeuroresearch, +1-773-250-0425; or media, Lisa Stafford of P.S.Communications, +1-630-986-8749, cell, +1-630-212-1226,lisa@pscommunicationsinc.com, for Chicago Institute of Neurosurgery andNeuroresearch
Web site: http://www.cinn.org/
Source: PRNewswire
Related Articles
- Senator Ted Kennedy's Death from Brain Cancer Sheds Light on Detection and Diagnosis of Brain Tumors
- NCCN Updates Breast Cancer and Breast Cancer Risk Reduction Guidelines
- Aurora Breast MRI of Beverly Hospital Provides Advanced Imaging Technology With the Aurora Dedicated Breast MRI System
- Are PET Scans Beneficial During Cancer Diagnosis, Staging and Monitoring?
- Wellness Lubbock Newest Imaging Center in Texas to Offer the Aurora Dedicated Breast MRI's Advanced Imaging Technology
- Legacy Good Samaritan Hospital Surgeons Find BSGI Effective in Determining Extent of Breast Cancer in Patients With Known Diagnosis
- Aurora Dedicated Breast MRI Now Available at the Comprehensive Breast Center of The Don and Sybil Harrington Cancer Center
- St. Louis Cancer and Breast Institute to Get New AccuBoost System for Breast Cancer
- Neopharm Clears a Key Hurdle: Brain Cancer Drug Advances, Takes Stock Price With It
- Study Says Brain Cancer Treatments Vary
 |
 |
User Comments (0)
RSS Feeds